After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.
Global Liver Institute Founder and CEO Donna Cryer joins Louise Campbell and Roger Green to discuss her personal challenges during the last part of 2023, the growing strength of the Global Liver Institute and the challenges facing GLI and the entire community in 2024.
Patient advocates Neeraj Mistry of the Fatty Liver Foundation and Jenn Leigh Jones of the Society for Sober Liver Survival join Louise Campbell and Roger Green to discuss the merging of their organizations and the impact of the new nomenclature on how patients might look at their disease.
HistoIndex Chief Scientific Officer Dean Tai joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss how advances in MASLD artificial intelligence will spur knowledge, insight and innovation in drug development and NITs.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
Surfing the MASH Tsunami kicks off its 2023 wrap-up conversations with Jeff Lazarus, the 2023 winner of the Distinguished Scientific Achievement Award from the American Liver Foundation. Wrapping up 2023 in Steatotic Liver Disease: A Discussion with Jeff Lazarus
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers a pivotal session on the new MASLD nomenclature, plus what the panelists found exciting and important about the developing class of triple agonists, at TLM 2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations covering NITs, artificial intelligence and bariatric surgery at TLM2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations of clinical trial results at TLM 2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers the four panelists’ general impressions of TLM2023, both the good and bad of it.
